# US 2006/0153775 A1 · Compounds for targeting endothelial cells, compositions containing the same and methods for their use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153775 A1
- Document ID: US20060153775A1
- Status: Published application
- Kind: A1
- Application number: 11/342,050
- Filed: 2006-01-27
- Published: 2006-07-13
- Earliest claimed: 2000-06-02
- Assignees: Bracco International B.V.
- Inventors: Mathew Von Wronski; Edmund Marinelli; Adrian Nunn; Radhakrishna Pillai; Kondareddiar Ramalingam; Michael Tweedle; Karen Linder; Palaniappa Nanjappan; Natarajan Raju
- Web page: https://patentgrep.com/patent/US20060153775A1

## CPC

- A61K 49/0067: {quantum dots, fluorescent nanocrystals}
- A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- A61K 49/14: Peptides, e.g. proteins
- A61K 49/223: {Microbubbles, hollow microspheres, free gas bubbles, gas microspheres}
- A61K 51/088: {conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10)}
- A61P 35/00: Antineoplastic agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- B82Y 10/00: Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
- B82Y 30/00: Nanotechnology for materials or surface science, e.g. nanocomposites
- C07K 7/06: having 5 to 11 amino acids
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides compounds for targeting endothelial cells, tumor cells or other cells that express the NP-1 receptor, compositions containing the same and methods for their use. Additionally, the present invention includes diagnostic, therapeutic and radiotherapeutic compositions useful for visualization, therapy or radiotherapy.

## Claims

### Claim 1

A composition for use in targeting endothelial cells, tumor cells or other cells which express NP-1, which comprises a compound of the formula (I)
A-L-B (I)
in which
A is a monomer, multimer or polymer of TKPPR, or a TKPPR analogue which specifically binds to NP-1 or cells that express NP-1 with avidity that is equal to or greater than TKPPR;
L is a linker; and
B is a substrate comprising a small particle.

### Claim 2 (depends on 1)

A composition according to claim 1, wherein B comprises a quantum dot.

### Claim 3 (depends on 1)

A process for preparing a compound of claim 1 comprising:
a) obtaining a monomer, multimer or polymer of TKPPR or an analogue thereof;
b) conjugating the monomer, multimer or polymer of TKPPR with the linker to give a compound of formula (IIb); and
A-L (IIb)
c) forming a covalent or non-covalent bond between a compound of formula (IIb) and the substrate B or forming a covalent bond between the substrate B and the linker to form a conjugate B-L, and
conjugating of the conjugate B-L with the monomer, multimer or polymer of TKPPR or an analogue thereof.

### Claim 4

A method of imaging an angiogenic site in a human or animal comprising:
a) administering to said human or animal a composition comprising a compound of the formula (I):
A-L-B (I)
in which
A is a monomer, multimer or polymer of TKPPR or a TKPPR analogue which specifically binds to NP-1 or cells which express NP-1 with avidity that is equal to or greater than TKPPR;
L is a linker; and
B is a substrate, where B comprises a detectable small particle; and
b) detecting said small particle.

### Claim 5

A method of imaging endothelial cells, tumor cells or other cells that express NP-1 in a human or animal comprising:
a) administering to said human or animal a composition comprising a compound of the formula (I)
A-L-B (II)
in which
A is a monomer, multimer or polymer of TKPPR or a TKPPR analogue which specifically binds to NP-1 or cells which express NP-1 with avidity that is equal to or greater than TKPPR;
L is a linker; and
B is a substrate, where B comprises a detectable small particle; and
b) detecting said small particle.

### Claim 6 (depends on 1)

A method of staging a tumor in a human or an animal comprising administering a composition comprising a compound of claim 1 and an optional detectable moiety to said human or animal and detecting said moiety in said human or animal.

### Claim 7 (depends on 1)

A method of screening at least one agent for the ability of said agent to target endothelial cells, tumor cells or other cells that express NP-1, comprising contacting said cells in vitro with a composition of claim 1 and an optional detectable moiety.

### Claim 8 (depends on 1)

A method for the therapeutic delivery in vivo of one or more small particles to a patient suffering from effects associated with angiogenesis-related disorders comprising administering a therapeutically effective amount of a composition of claim 1.

### Claim 9 (depends on 1)

A method of treating an individual exhibiting effects of an angiogenesis-related disorder comprising administering a therapeutically effective amount of a composition of claim 1, optionally further comprising a therapeutic moiety.

### Claim 10 (depends on 1)

A method for treating a human or animal with a tumor or angiogenesis-related disease comprising administering to said human or animal a therapeutically effective amount of a composition according to claim 1, optionally further comprising a therapeutic moiety.

### Claim 11

A compound having the following structure:

### Claim 12 (depends on 11)

A method of synthesizing the compound of claim 11, comprising the following steps:
(a) reacting Diacid with HATU and NAHCO3 to yield an Fmoc tetramer;
(b) dissolving said Fmoc tetramer in acetonitrile to yield a crude amine; and
(c) treating the crude amine with dichloromethane to yield D50.

### Claim 13 (depends on 11)

A composition comprising the compound of claim 11 conjugated to a small particle.

### Claim 14 (depends on 13)

A composition for use in targeting endothelial cells, tumor cells or other cells which express NP-1, which comprises a compound of claim 13.

### Claim 15 (depends on 13)

A method of imaging an angiogenic site in a human or animal comprising administering to said human or animal a composition of claim 13, optionally further comprising a detectable moiety.

### Claim 16 (depends on 13)

A method of imaging endothelial cells, tumor cells or other cells that express NP-1 in a human or animal comprising administering to said human or animal a composition of claim 13, optionally further comprising a detectable moiety.

### Claim 17 (depends on 13)

A method for the therapeutic delivery in vivo of one or more small particles to a patient suffering from effects associated with angiogenesis-related disorders comprising administering a therapeutically effective amount of a composition of claim 13.

### Claim 18 (depends on 13)

A method of treating an individual exhibiting effects of a tumor or an angiogenesis-related disorder comprising administering a therapeutically effective amount of a composition of claim 13, optionally further comprising a therapeutic moiety.

### Claim 19

A compound having the following structure:

### Claim 20 (depends on 19)

A method of synthesizing the structure of claim 19, comprising the following steps:
(a) constructing a peptide sequence on preloaded H-Arg(Pmc)-O-2-chlrotrityl chloride resin;
(b) cleaving the peptide sequence from the resin; and
(c) isolating the peptide sequence.

### Claim 21 (depends on 19)

A composition comprising the compound of claim 19 conjugated to a small particle.

### Claim 22 (depends on 19)

A composition for use in targeting endothelial cells, tumor cells or other cells which express NP-1, which comprises a compound of claim 19.

### Claim 23 (depends on 22)

A method of imaging an angiogenic site in a human or animal comprising administering to said human or animal a composition of claim 22, optionally further comprising a detectable moiety.

### Claim 24 (depends on 22)

A method of imaging endothelial cells, tumor cells or other cells that express NP-1 in a human or animal comprising administering to said human or animal a composition of claim 22, optionally further comprising a detectable moiety.

### Claim 25 (depends on 22)

A method for the therapeutic delivery in vivo of one or more small particles to a patient suffering from effects associated with angiogenesis-related disorders comprising administering a therapeutically effective amount of a composition of claim 22.

### Claim 26 (depends on 22)

A method of treating an individual exhibiting effects of a tumor or an angiogenesis-related disorder comprising administering a therapeutically effective amount of a composition of claim 22, optionally further comprising a therapeutic moiety.

### Claim 27

A method for treating a human or animal with a tumor or angiogenesis-related disease comprising administering to said human or animal a therapeutically effective amount of a composition comprising a radiolabelled TKPPR tetramer.

### Claim 28 (depends on 27)

The method of claim 27, wherein the tumor or angiogenesis-related disease is prostate cancer.

### Claim 29 (depends on 27)

The method of claim 27, wherein the composition further comprises a chelator.

### Claim 30

A composition for imaging or treating a human or animal with prostate cancer which comprises a compound of the formula (I)
A-L-B (I)
in which
A is a monomer, multimer or polymer of TKPPR, or a TKPPR analogue which specifically binds to NP-1 or cells that express NP-1 with avidity that is equal to or greater than TKPPR;
L is a linker; and
B is a substrate.

### Claim 31 (depends on 30)

The composition of claim 30, wherein the substrate B is a detectable label.

### Claim 32 (depends on 30)

The composition of claim 30, wherein the substrate B is a chelator for a radiotherapeutic metal.

### Claim 33 (depends on 30)

The composition of claim 30, wherein the substrate B is a bioactive agent with a therapeutic effect.

### Claim 34 (depends on 32, 33)

A method of treating a human or animal with prostate cancer comprising administering a therapeutically effective amount of a composition of any one of claims 32 or 33.

### Claim 35 (depends on 31)

A method of imaging a human or animal with prostate cancer comprising administering a detectable amount of a composition of claim 31 and detecting the composition.

### Claim 36

A compound having the following structure:

### Claim 37 (depends on 36)

A method of imaging a human or animal with prostate cancer comprising
administering a detectable amount of a composition comprising the compound of claim 36, and
detecting the composition.
